stockrow
Monday 9 November 2026
Export BGLC’s income statement to Excel — free account
BioNexus Gene Lab Corp.
BGLCBasic Materials Specialty Chemicals
BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024.
- Revenue
- −96.6%
- EPS
- +64.7%
- Free cash flow
- +44.3%
Quarter to June 2026, against a year earlier
0.83
0.03
−3.49%
Follow BGLC
Alert me
BioNexus Gene Lab Corp. (BGLC) P/E ratio
BioNexus Gene Lab Corp. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 9,802× (October 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 485× | 124.26% |
| FY2020 | 216× | 372.90% |
| FY2019 | 45.7× | 0.00% |
| FY2018 | 45.7× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 29 more quarters | Free account |
Against its own ten years
Low 0.0×
High 9,802×
Ten-year median
0.0×
Current reading's percentile
56
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LOOP Loop Industries, Inc. compare | n/m |
| NTIC Northern Technologies International Corporation compare | n/m |
| BGLC BioNexus Gene Lab Corp. | n/m |
| SNES Senestech, Inc. compare | n/m |
| FEAM 5E Advanced Materials, Inc. compare | n/m |
| CITR CitroTech Inc. compare | n/m |
| BON Bon Natural Life Limited compare | 0.9× |
| CNEY CN Energy Group. Inc. compare | 2.8× |
| YMAT J-Star Holding Co., Ltd compare | — |
| Specialty Chemicals industry median | 26.4× |
| Basic Materials sector median | 19.1× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)